Department Of Gastroenterology 1
1. Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohns Disease
2. Global multi-societies endorsement of the MAFLD definition
3. Global multi-societies endorsement of the MAFLD definition
4. Global multi-societies endorsement of the MAFLD definition
5. Global multi-societies endorsement of the MAFLD definition
6. Global multi-societies endorsement of the MAFLD definition
7. Global multi-societies endorsement of the MAFLD definition
8. Global multi-societies endorsement of the MAFLD definition
9. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
10. Brief interventions to prevent NCDs and their nutritional complications in primary care setting
11. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
12. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
13. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
14. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
15. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
16. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
17. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
18. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
19. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
20. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
21. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
22. Global Hospitalization Trends for Crohns Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses
23. Global Hospitalization Trends for Crohns Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses
24. Global Hospitalization Trends for Crohns Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses
25. Global Hospitalization Trends for Crohns Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses
26. Global Hospitalization Trends for Crohns Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses
27. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
28. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
29. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
30. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
31. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
32. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
33. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
34. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
35. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
36. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
37. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
38. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
39. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
40. Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients
41. Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021
42. Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021
43. Global evolution of inflammatory bowel disease across epidemiologic stages
44. Global evolution of inflammatory bowel disease across epidemiologic stages
45. Global evolution of inflammatory bowel disease across epidemiologic stages
46. Global evolution of inflammatory bowel disease across epidemiologic stages
47. Global evolution of inflammatory bowel disease across epidemiologic stages
48. Global evolution of inflammatory bowel disease across epidemiologic stages
49. A second update on mapping the human genetic architecture of COVID-19
50. A second update on mapping the human genetic architecture of COVID-19
1 2 3